Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Purpose
Ponatinib is a novel tyrosine kinase inhibitor (TKI) specifically designed to inhibit native and mutated BCR–ABL. In the United States, ponatinib has received accelerated approval for adults with T315I-positive chronic myeloid leukemia (CML) or T315I (gatekeeper mutation)-positive, Philadelphia chromosome-positive, acute lymphoblastic le...
Alternative Titles
Full title
Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5344956
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5344956
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s00280-017-3240-x
